Serán Bioscience, a contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical, and manufacturing services to pharmaceutical and biotechnology companies, has announced a strategic growth transaction of more than $200 million, which will support Serán’s continued growth and construction of a new commercial-scale manufacturing facility.
 
Bain Capital Life Sciences led the transaction while existing investor Vivo Capital remains a key shareholder in the company. The new facility will enable the company to provide integrated capabilities across multiple drug delivery and final dose formats providing solutions for clients from early development to commercial supply.

New Commercial Facility

The facility will be completed in 2026 and will support oral, pulmonary, and nasal delivery modalities with commercial-scale particle engineering solutions, including spray drying, hot melt extrusion, nano-milling, and fluid-bed manufacturing, as well as comprehensive finished dose capabilities including granulation, tableting, coating, encapsulation, powder filling, including for modified release products. An adjacent facility, already under construction, will enable extensive packaging, labeling, serialization, and distribution capabilities.
 
“This transaction is a significant milestone in Serán’s evolution, which will enable us to rapidly scale our clinical manufacturing capability to support launches of new medicines, as well as serve new clients seeking state-of-the-art commercial capacity,” said Dan Smithey, Co-Founder and CEO of Serán. “We are proud to have the additional support and resources of a preeminent life sciences investor in Bain Capital who shares our vision for expanding Serán’s science-based drug development capabilities to enable commercial manufacturing of complex medicines.”
 
“We are impressed with Serán’s differentiated expertise and capabilities in drug development and clinical manufacturing. We believe the Company is well-positioned to benefit from long-term secular tailwinds given the importance of drug delivery technology to help address increasing challenges facing next generation oral drugs,” said Will Cozean, a Managing Director at Bain Capital.
 
Serán has over 200 team members, with more than 150 being scientists and engineers. It plans to hire up to 150 additional employees as the campus in Bend, Oregon expands to nearly 200,000 square feet.